PolyPid PYPD 深 沪
已收盘 09-19 16:00:00 美东时间
3.45
-0.050
-1.43%
华盛通- 最 高3.52
- 今 开3.49
- 成交量 4.29万股
- 最 低 3.43
- 昨 收 3.50
- 总市值 5484.53万
- 52周最高 3.93
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 2.30
- 委 比 90.06%
- 总股本 1589.72万
- 历史最高 583.50
- 量 比 1.70
- 振 幅 2.57%
- 历史最低 2.30
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
PolyPid Ltd. will present at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025, and participate in one-on-one meetings. Management will also attend the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. Investors can arrange meetings via Lytham Partners or ROTH representatives. PolyPid, a biopharma company, aims to improve surgical outcomes using its PLEX technology. Its lead product, D-PLEX₁₀₀, ...
09-17 12:44
PolyPid Completes Key GMP Inspection for D-PLEX100 Manufacturing Readiness
The latest update is out from PolyPid ( ($PYPD) ). PolyPid Ltd. announced on Se...
09-16 20:59
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
PolyPid Ltd. successfully completed its fourth consecutive GMP inspection, confirming its manufacturing facility meets EU and US standards. This milestone supports its planned 2026 NDA submission for D-PLEX₁₀₀, its lead product for preventing surgical site infections, following positive Phase 3 results. The inspection also prepares the company for FDA inspection and potential market entry in both the U.S. and Europe. D-PLEX₁₀₀ has shown significa...
09-16 12:30
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, announced that its senior management will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025. The company will host a fireside chat with H.C. Wainwright Managing Director Brandon Folkes on September 8, alongside virtual and in-person investor meetings. PolyPid specializes in controlled drug delivery u...
09-03 12:30
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company, announced that Dalit Hazan, its Deputy CEO and EVP of R&D, Clinical, and Regulatory Affairs, will present on "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" at the 14th Israel Controlled Release Society (ICRS) Conference on September 7-9, 2025. The presentation, scheduled for September 7, 2025, from 5:25 PM to 5:45 PM local time, will focus on a...
09-02 12:30
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.
08-14 01:40
PolyPid Reports Positive Phase 3 Results and Strengthens Leadership
An announcement from PolyPid ( ($PYPD) ) is now available. On August 11, 2025, ...
08-13 19:57
PolyPid GAAP EPS of -$0.78
PolyPid press release (NASDAQ:PYPD): Q2 GAAP EPS of -$0.78. As of June 30, 2025, the company had cash and cash equivalents and short-term deposits in the amount of $29.5 million, compared to $15.6 mil...
08-13 19:39
